ASCO 2020：11项中国研究工作入选口头报告，17项Poster报告

深受全球新冠疫情制约，原定于5月29日~6月2日在纽约举行的澳大利亚临床学会（ASCO）年会今年将首次以线上表现形式举办，这是目前最大规模的线上盛会。今天，全会的简介题目公布，共103个sessions，中的国共有11项研究成果获选口头报告，17项获选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或拉帕替尼加卡培他中洲用于HER2+转到功能性乳腺腺癌（PHOEBE）：一项III期随机次测试。

首站：转到功能性乳腺腺癌

所写：中的国医学科学院养老院徐兵河任教、马飞任教，北京大学附属养老院胡夕春任教等

简介号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴功能性乳腺腺癌标准化疗后卡培他中洲维持节拍低剂量的III期次测试（SYSUCC-001）。

首站：乳腺腺癌—发散/周边地区/特别设计化疗

所写：中的山大学防治中的心王于树森任教等

简介号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

并用转到功能性脑的表型特征来预测脑脊液中的周而复始DNA探测的概率: 新工具对抗老对手

首站：新工具消除老情况

所写：李美芹 李德兰等

简介号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为早期肝线粒体腺癌的三线化疗：一项开放附加、随机、多中的心II/III期次测试。

首站：消化道腺癌—胃部十二指肠、癌变和实无

所写：四川大学华西养老院毕锋任教、程子华朝阳养老院秦叔逵任教等

简介号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中的国早期肝腺胃部癌状阿帕替尼防区化疗：一项随机、安慰剂依此、双盲III期研究成果

首站：消化道腺癌—胃部十二指肠、癌变和实无

所写：程子华朝阳养老院秦叔逵任教、四川大学华西养老院李秋任教等

简介号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

早期患上功能性卵巢腺癌二次线粒体减灭术的一项随机III期次测试：SOC1 / SGOG-OV2。

不定期：妇科腺胃部癌

所写：北京大学附属中的山养老院臧荣余任教等

简介：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈腺癌根治功能性子宫切除术后特别设计化疗中的的序贯放低剂量对比单独放疗或同步放低剂量（STARS研究成果）：一项随机、依此、开放附加的III期次测试。

全会：妇科腺胃部癌

所写：中的山大学防治中的心新华任教、刘继红任教等

简介号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：特别设计吉非替尼对比低剂量用于可切除的EGFR变异的N1-N2期NSCLC-随机III期临床次测试的事与愿违总体求生存系统功能性。

不定期：肺腺癌—非小线粒体发散-周边地区/小线粒体/其他腰部

所写：广东省人民养老院吴一龙任教等

简介号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR变异少转到非小线粒体肺腺胃部癌状三线乙酰激酶类似物重新组建或不重新组建积极第一线发散放疗：III期开放附加临床随机次测试（SINDAS）的中的期结果（NCT02893332）。

不定期：肺腺癌-非小线粒体转到

所写：四川人民养老院曾铭任教等

简介：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序功能性死亡-1（PD-1）的人源化IgG4基因工程重新组建阿昔替尼用于转到功能性口腔腺胃部癌症状的Ib期研究成果的总求生存期和生物；也系统功能性。

不定期：腺胃部癌/皮肤腺癌

所写：北京大学养老院郭军、盛锡楠任教等

简介：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的稳定功能性和结果：通用CAR-T线粒体首次人体次测试化疗患上/难治功能性T线粒体急功能性淋巴线粒体白血病（r/r T-ALL）的稳定功能性和。全会：研发中的的化疗技术-免疫化疗。所写：王于欣欣等简介：3013标语：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在早期十二指肠大块线粒体腺胃部癌状中的的技术的发展：一项随机的开放附加II期次测试（ORIENT-2）。全会：消化道腺癌-胃部十二指肠腺癌、癌变腺癌和实无道腺癌所写：徐建明任教等简介：4511标语：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D免疫CAR-T线粒体对髓母线粒体瘤的禁绝功能性化疗全会：中的枢神经系统所写：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、赵旭东简介：2522标语。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在早期错配修复毛病症状中的的技术的发展全会：研发中的的化疗学-免疫化疗所写：沈琳任教等简介：3021标语。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART化疗患上/难治功能性ACUTE淋巴线粒体白血病/淋巴瘤的首例人体临床次测试全会: 研发功能性化疗学-免疫化疗所写简介：张明志，杨林等简介：3026标语: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）重新组建技术的发展于早期实质瘤症状的Ib期研究成果全会：发展功能性化疗学--分子结构靶向药物和生态学所写：龚继芳，沈琳任教等简介：3523标语：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin重新组建类固醇和nedaplatin化疗患上功能性或转到功能性十二指肠大块线粒体腺癌（ESCC）症状的II期研究成果。全会：消化道腺癌-胃部十二指肠、癌变和实无道腺癌的研究成果所写：王于志爆冷，李玉红，王于德申，王于凤华，任超，谭琼 王于志爆冷、李玉红、王于德深、王于凤华、任超、谭琼简介：4522标语：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全会：消化道腺癌-胃部十二指肠腺癌、癌变腺癌和实无管腺癌的防区化疗所写：宋艳等简介：4524标语：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体环状RNA分类器用于初始活检时探测高等级腺癌的尿液外体环状RNA分类器：一项多中的心的回顾功能性研究成果全会：周而复始系统睾丸腺胃部癌---腺癌、皮肤腺癌和腺癌所写简介：Liaoyuan Li等简介：5522标语。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 发散早期宫颈腺癌并发低剂量后的特别设计低剂量全会: 妇科腺胃部癌所写简介： 李珉珉等简介：6031标语：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼化疗病变髓功能性腺癌的差异功能性：基于ALTER01031次测试的系统功能性。会衹：头颈部所写：天津市养老院高明任教简介：6526标语。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼化疗后症状剧情的制约: ALTER01031的亚组系统功能性全会：头颈部所写：天津市养老院高明任教简介：6527标语。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA系统功能性预测I-IIIA期非小线粒体肺腺癌（NSCLC）症状术后患上: GASTO1035和GASTO1018的结果全会：肺腺癌-非小线粒体发散-周边地区功能性/小线粒体/小线粒体/其他胸科腺胃部癌所写：Si-Yu Wang等简介：9023标语：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小线粒体肺腺癌（NSCLC）中的EGFR乙酰激酶类似物的新型耐药功能全会:肺腺癌-非小线粒体转到功能性肺腺癌所写简介：赵昕，金玲玲，满宇，欧秋香，华宝，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧秋香、华宝、薛武、杨绍、范敏简介：9528标语：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1次测试中的早期腺胃部癌总求生存的替代往南全会：腺胃部癌/皮肤腺癌所写：聂润聪，袁书爆冷，李元芳，陈英波，周志伟 聂润聪、袁书爆冷、李元芳、陈英波、周志伟简介：10030标语：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼化疗患上或转到功能性原发功能性恶功能性骨症状的II期研究成果全会： 病症所写：唐丽娜，牛晓辉，王于震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王于振、蔡启庆、涂崇奇、范正福、杨瑶简介：11525标语。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在早期病症症状多线化疗中的的稳定功能性和。全会：病症所写：姚伟涛，王于家爆冷，张鹏，王于欣，杜新辉，田志浩，牛晓颖 姚伟涛、王于家爆冷、张鹏、王于鑫、杜鑫辉、田志超、牛晓英简介：11526标语：414